Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment

Neoplasia

Volumn 7, Issue 10, 2005, Pages 883-893

  Wemmert, Silke ^a   Ketter, Ralf ^a   Rahnenführer, Jörg ^b   Beerenwinkel, Niko ^b   Strowitzki, Martin ^a   Feiden, Wolfgang ^a   Hartmann, Christian ^c   Lengauer, Thomas ^b   Stockhammer, Florian ^c   Zang, Klaus D ^a   Meese, Eckart ^a   Steudel, Wolf Ingo ^a   Von Deimling, Andreas ^c   Urbschat, Steffi ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CGH; Glioblastoma multiforme; LOH; Survival; TMZ

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; MICROSATELLITE DNA; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 10Q; CHROMOSOME 13Q; CHROMOSOME 7; CHROMOSOME 9P; CHROMOSOME DELETION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENETIC MARKER; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; UNIVARIATE ANALYSIS; AGE; BIOLOGICAL MODEL; BRAIN TUMOR; CHEMISTRY; CHROMOSOME; CHROMOSOME 10; CHROMOSOME 9; CYTOGENETICS; GENE DELETION; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; TIME; TREATMENT OUTCOME; ULTRASTRUCTURE;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 9; CYTOGENETICS; DACARBAZINE; FEMALE; GENE DELETION; GENETIC MARKERS; GLIOBLASTOMA; GLIOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MODELS, GENETIC; MULTIVARIATE ANALYSIS; NUCLEIC ACID HYBRIDIZATION; PARAFFIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644874646     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05307     Document Type: Article

References (57)

1. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, and Louis DN (1993). Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3, 19-26.
2. Kleihues P and Cavenee WK (2000). WHO Classification, Tumors of the Central Nervous System. IARC Press, Lyon, France.
3. Tada K, Shiraishi S, Kamiryo T, Nakamura H, Hirano H, Kuratsu JI, Kochi M, Saya H, and Ushio Y (2001). Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 95, 651-659.
4. Stewart LA (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018.
5. Devaux BC, O'Fallon JR, and Kelly PJ (1993). Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78, 767-775.
6. Albert FK, Forsting M, Sartor K, Adams HP, and Kunze S (1994). Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on re-growth and prognosis. Neurosurgery 34, 45-60.
7. Burger PC and Green SB (1987). Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59, 1617-1625.
8. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, et al. (2000). A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83, 588-593.
9. Osoba D, Brada M, Yung WKA, and Prados M (2000). Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18, 1481-1491.
10. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, et al. (2001). Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12, 259-266.
11. Bigner SH, Mark J, Burger PC, Mahaley MS Jr, Bullard DE, Muhlbaier LH, and Bigner DD (1988). Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 48, 405-411.
12. Thiel G, Losanowa T, Kintzel D, Nisch G, Martin H, Vorpahl K, and Witkowski R (1992). Karyotypes in 90 human gliomas. Cancer Genet Cytogenet 58, 109-120.
13. Louis DN and Gusella JF (1995). A tiger behind many doors-multiple genetic pathways to malignant glioma. Trends Genet 11, 412-415.
14. Fults D, Brockmeyer D, Tullous MW, Pedone CA, and Cawthon RM (1992). p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52, 674-679.
15. Ueki K, Ono Y, Hensen JW, Efird JT, von Deimling A, and Louis DN (1996). CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56, 150-153.
16. Harbour JW and Dean DC (2000). The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14, 2393-2409.
17. Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, and McLendon RE (2002). Molecular markers of prognosis in astrocytic tumors. Cancer 94, 2688-2697.
18. Terada K, Tamiya T, Daido S, Kambara H, Tanaka H, Ono Y, Matsumoto K, Ito S, Ouchida M, Ohmoto T, et al. (2002). Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neuro-Oncol 58, 107-114.
19. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD, Louis DN, Fimmers R, and von Deimling A (2002). Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61, 321-328.
20. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, and Schlegel U (2000). Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neuro-Oncol 48, 89-94.
21. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50, 6119-6129.
22. Gerson SL (2002). Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20, 2388-2399.
23. Stupp R, Gander M, Leyvraz S, and Newlands E (2001). Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2, 552-560.
24. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, and Herman JG (2000). Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343, 1350-1354.
25. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59, 793-797.
26. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Guirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, et al. (2004). CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10, 4933-4938.
27. 6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10, 1871-1874.
28. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de TN, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003.
29. Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, and Feuerstein BG (2001). Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61, 7683-7688.
30. Wessels PH, Twijnstra A, Kessels AG, Krijne-Kubat B, Theunissen PH, Ummelen MI, Ramaekers FC, and Hopman AH (2002). Gain of chromosome 7, as detected by mosome in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer 33, 279-284.
31. Huncharek M and Kupelnick B (2000). Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 12, 107-112.
32. Muracciole X, Romain S, Dufour H, Palmari J, Chinot O, Ouafik L, Grisoli F, Branger DF, and Martin PM (2002). PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 52, 592-598.
33. De Souza NP, Maciel CM, Kawamura MT, Oliveira JA, Teixeira A, Carvalho MG, and Alves G (2001). Molecular analysis of CDKN2 (p16) in gliomas associated with clinical data. Oncol Rep 8, 1039-1043.
34. James CD, Galanis E, Frederick L, Kimmel DW, Cunningham JM, Atherton-Skaff PJ, O'Fallon JR, Jenkins RB, Buckner JC, Hunter SB, et al. (1999). Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol 15, 547-553.
35. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, et al. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90, 1473-1479.
36. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, and Pinkel D (1994). Optimizing comparative genomic hybridization for analysis of DNA-sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10, 231-243.
37. n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. Am J Pathol 141, 777-782.
38. Louis DN, Rubio MP, Correa KM, Gusella JF, and von Deimling A (1993). Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 52, 507-515.
39. Budowle B, Koons BW, and Errera JD (1996). Multiplex amplification and typing procedure for the loci D1S80 and amelogenin. J Forensic Sci 41, 660-663.
40. Shapiro WR, Green SB, Burger PC, Mahaley MS Jr, Selker RG, Van Gilder JC, Robertson JT, Ransohoff J, Mealey J Jr, Strike TA, et al. (1989). Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71, 1-9.
41. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, Malkin MG, Mealey JJ Jr, Neal JH, Olson J, et al. (2002). The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51, 343-355.
42. Deutsch M, Green SB, Strike TA, Burger PC, Robertson JT, Selker RG, Shapiro WR, Mealey J Jr, Ransohoff J, Paoletti P, et al. (1989). Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16, 1389-1396.
43. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
44. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, and Karageorgis P (2005). Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23, 2372-2377.
45. Corry J, Smith JG, Wirth A, Quong G, and Liew KH (1998). Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41, 615-620.
46. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, and Reifenberger G (2004). Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14, 121-130.
47. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, and Seizinger BR (1992). Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 52, 4277-4279.
48. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, and Collins VP (1994). Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145, 1175-1190.
49. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, and von Deimling A (1995). Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54, 91-95.
50. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, et al. (2000). Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18, 636-645.
51. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, et al. (2000). Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59, 544-558.
52. Loeper S, Romeike BFM, Heckmann N, Jung V, Henn W, Feiden W, Zang KD, and Urbschat S (2001). Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenet Cell Genet 94, 1-8.
53. Jung V, Romeike BF, Henn W, Feiden W, Moringlane JR, Zang KD, and Urbschat S (1999). Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J Neuropathol Exp Neurol 58, 993-999.
54. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, and Schlegel U (2001). Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (Berl) 101, 311-320.
55. Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, Banerjee R, Trinkaus K, Lytle R, and Perry A (2003). Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 62, 1118-1128.
56. Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, and Vikkula M (2003). Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 29, 462-471.
57. Puduvalli VK, Kyritsis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, and Bruner JM (2000). Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol 17, 963-969.